Walgreens has announced a partnership with the Cardiovascular Research Foundation (CRF) for the PREVUE-VALVE population-based clinical trial.

Aimed at quantifying the prevalence of valvular heart disease (VHD) among older people in the US, the study will pave way for new therapies and tools development for detection and diagnosis of valvular heart disease (VHD).

The partnership between Walgreens and CRF is expected to strengthen participant recruitment efforts for maximising diversity and access in the ongoing trial.

Leveraging its national presence, relationships with communities and data-driven clinical trials solutions, Walgreens will help identify and reach potential participants for the study.

CRF Clinical and Outcomes Research director David Cohen said: “The ageing population has led to a surge in the incidence and prevalence of valvular heart disease in the US. Unfortunately, many patients with valvular heart disease remain untreated or receive treatment later than recommended due to various barriers.

“Partnering with Walgreens will help us engage a broader and more representative patient population for enrolment in the PREVUE-VALVE study so that we can improve our ability to diagnose valvular heart disease before the onset of irreversible cardiac damage, which will allow for more timely treatment and ultimately, better health outcomes, for our patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the partnership, Walgreens will be responsible for providing patient recruitment services to support the trial.

Trial subjects will have all procedures performed at their homes to improve convenience and engagement.

Walgreens will utilise longitudinal pharmacy and social determinants of health insights and automated recruitment selection software to reach eligible subjects for enrolment.

Topline data from the PREVUE-VALVE trial are expected in 2025.